Skip to main navigation
  • Careers
  • Contact Us
Exelixis
  • Our Story
    • Mission
    • Leadership
    • Board of Directors
    • Collaborations
  • Medicines
    • Our Medicines
    • Access
  • Research & Development
    • Research and Development
    • Pipeline
      • Pipeline Overview
      • Early-Stage Compounds
      • Cabozantinib Pipeline
      • Other Partnered Programs
    • Clinical Trials
  • Impact
    • Stories
    • Grants & Giving
    • Corporate Values & Sustainability
  • Investors & Media
    • Investors Overview
    • News and Events
      • Press Releases
      • Event Calendar
      • Media Resources
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
      • Earnings Estimates
    • Financial Information
      • Annual Reports
      • SEC Filings
      • Interactive Analyst Center
    • Investor Resources
      • Investor FAQs
      • Corporate Values & Sustainability
      • Information Request
    • Corporate Governance
      • Corporate Governance Documents and Information
      • Leadership
      • Board of Directors
      • Committee Composition and Charters
    • Contact IR
Select Page

Investors & Media

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
Audit Committee Compensation Committee Nominating and Corporate Governance Research & Development Committee Risk Committee
Carl B. Feldbaum, Esq. Nominating and Corporate Governance Risk Committee
Maria C. Freire, Ph.D. Audit Committee Research & Development Committee Risk Committee
Alan M. Garber, M.D., Ph.D. Nominating and Corporate Governance Research & Development Committee
Vincent Marchesi, M.D., Ph.D. Compensation Committee Research & Development Committee
Stelios Papadopoulos, Ph.D. Audit Committee Compensation Committee Research & Development Committee
George Poste, DVM, Ph.D. Research & Development Committee Risk Committee
Julie Anne Smith Audit Committee Compensation Committee
Lance Willsey, M.D. Compensation Committee Research & Development Committee
Jacqueline Wright Nominating and Corporate Governance Risk Committee
Jack L. Wyszomierski Audit Committee Nominating and Corporate Governance
= Chairperson = Member = Financial Expert

Investor Relations

  • Investors Overview
  • News & Events
    • Press Releases
    • Event Calendar
    • Media Resources
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
    • Earnings Estimates
  • Financial Information
    • Annual Reports
    • SEC Filings
    • Interactive Analyst Center
  • Investor Resources
    • Investor FAQs
    • Corporate Values & Sustainability
    • Information Request
  • Corporate Governance
    • Corporate Governance Documents and Information
    • Leadership
    • Board of Directors
    • Committee Composition and Charters
  • Contact IR

Receive Email Alerts

Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Sign Up.
Required fields denoted by an asterisk ().
Alert type

Shareholder Tools

  • Information Request
  • Print Page
  • Email Alerts
  • RSS
Tweets by ExelixisInc

Our Story

  • Mission
  • Leadership
  • Board of Directors
  • Collaborations

Medicines

  • Our Medicines
  • Access

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Trials

Impact

  • Stories
  • Grants & Giving
  • Corporate Values & Sustainability

Investors & Media

    Investors & Media

    • Investors Overview
    • News & Events
    • Stock Information
    • Financial Information
    • Investor Resources
    • Corporate Governance
    • Contact IR
  • Facebook
  • Twitter
© Exelixis, Inc. 2023
  • Ethics & Compliance
  •  Privacy
  •  Terms of Use

This website uses cookies to improve and personalize content and for tracking and analytics. You can learn more from our Privacy Statement.

OK